We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Diagnostic Test Uses Light to Detect Malaria without Blood Samples

By LabMedica International staff writers
Posted on 09 Jan 2023

Rapid tests, which are easy to deploy and require minimal equipment, provide an important diagnostic tool in the ongoing effort against malaria, which affects more than 250 million people around the world annually. More...

While the advent of these tests has greatly advanced diagnosis in regions where the disease is endemic, they still involve invasive blood draws from patients, which require skilled medical personnel and pose additional safety risks. Now, a team of scientists is developing an alternative: a rapid diagnostic test that uses light to diagnose the often deadly disease - no blood draws or finger pricks needed.

Current rapid malaria tests involve applying a blood sample to a testing strip that can detect the presence of malaria-causing plasmodium parasites in red blood cells. Such tests can be administered at the point of care and provide results in about 20 minutes, but also are inadequate for detection of asymptomatic infections where the level of parasites in blood is low. The team of scientists led by Johns Hopkins University (Baltimore, MD, USA) has improved on that model through the development of a hand-held screening device that can scan a patient’s arm or finger to detect the presence of malaria, eliminating the need to draw blood. Called ParaSpy Plus, the technology depends on an optical fiber probe that combines two spectroscopy modalities, label-free Raman spectroscopy and diffuse reflectance spectroscopy, or DRS, to noninvasively quantify malaria parasites in red blood cells.

Thanks to the fiber probe, Raman and DRS measurements are sequentially performed in vivo without sampling blood. When collected by the device, the measurements will then directly feed into artificial intelligence algorithms that can provide a quick and accurate diagnosis. The team plans to integrate its new sensing technology and AI software into a single portable screening device. And without any blood draws or sample preparation, the device can be used to screen for malaria outside of a clinical setting, such as in schools or community centers. The team expects that at the end of the three-year project period, the prototype will be ready for large-scale validation via clinical studies in different malaria-endemic regions. ParaSpy Plus will also be adaptable to the diagnosis and treatment of many other diseases, according to the team.

“With our proposed method, there are no invasive finger-pricks. Instead, we are working on a way to diagnose whether a person has malaria through non-invasive measurements using near-infrared light,” said team leader Ishan Barman, an associate professor of mechanical engineering in the Whiting School of Engineering. “The secondary goal of our work is to explore the capability of this platform for the diagnosis of diseases with high prevalence among the same populations, such as anemia and sickle cell disease.”

Related Links:
Johns Hopkins University 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.